Canterbury DHB

Context

Treatment of Newly-Diagnosed Non-trial Patients

First Line Treatment

Before starting treatment, consider whether treatment is palliative with the aim of causing minimal treatment-related toxicity, or whether it aims to achieve prolonged disease-free survival in the hope that this produces a survival benefit. Relevant factors are:

There are now three funded options to choose from in NZ for patients who need treatment:

  1. Fit patients, defined as normal creatinine clearance and low co-morbidity score (go go), and without 17p deletion or TP53 mutation should receive FC-Rituximab as front-line therapy.
  2. Treatment naïve patients who are not able to tolerate full-dose FC-Rituximab and with CIRS score of <6 now qualify for Bendamustine as first-line treatment through the special authority scheme.
  3. Obinutuzumab, a second generation anti-CD20 monoclonal antibody, is also approved for use in combination with chlorambucil in patients who are not able to tolerate full dose FC-Rituximab, have CIRS score >6 and/or CrCl <70 mL/min and are obinutuzumab naïve.

Patients with relevant co-morbidity (slow go) should be treated with chlorambucil or dose-modified FC to achieve symptom control.

Patients with symptomatic disease and del(17p) respond poorly to FCR and should be considered for alternative first line therapy, e.g. high dose methylprednisolone ± rituximab, alemtuzumab and allogeneic transplantation.

For a discussion of first line treatment options in CLL, see:

Geographical Variations in Practice

It should be noted that the recommendations for 1st line treatment and beyond in NZ are influenced by the economic availability of drugs. In Europe the most commonly prescribed treatment for non-intensive patients is bendamustine-rituximab, and chlorambucil is used by less than 10% of haematologists. Similarly, in the relapsed setting the most commonly used drug in Canada is ibrutinib. Ibrutinib is not funded in NZ at the time of writing.

In This Section

Chlorambucil

Fludarabine and Cyclophosphamide

Bendamustine and Rituximab

Obinutuzumab and Chlorambucil

Rituximab

Chlorambucil

This is the simplest treatment and generally well tolerated although neutropenia is common at higher doses (see below). The overall response rate varies between 30-60% according to the individual regimen, but there are few complete remissions, and progression-free survival and time to next treatment is usually shorter than alternative regimens.

No benefit has been shown for the addition of prednisone (unless there are auto-immune cytopenias) or for different regimens, e.g. continuous v. intermittent. Some example regimens are given below.

Chlorambucil 40 mg/m2 PO every 28 days was compared with single agent fludarabine 25 mg/m2 IV on days 1-5 every 28 days. Complete remission occurred in 4% and partial remission in 33%. The median duration of remission and progression-free survival were both 14 months. Grade 3/4 neutropenia occurred in 19% and grade 3/4 toxicity of any type in 44% (Rai, K. R., et al. (2000). N Engl J Med 343(24): 1750-1757.)

The same regimen was compared with alemtuzumab and median time to alternative treatment was 14.7 months. The overall response rate was 55%. (Hillmen, P., et al. (2007). Journal of Clinical Oncology 25(35): 5616-5623.)

Chlorambucil 30 mg/d for 4 days every week for 4 weeks, then 30 mg/d for 4 days every 2 weeks for 8 weeks. The median time to treatment failure in treated and untreated patients was 13 and 104 months respectively. (Summerfield, G. P., et al. (2002). Br J Haematol 116(4): 781-786.)

Chlorambucil 0.8 mg/kg on days 1 and 15 every 4 weeks was compared with bendamustine. The median PFS for the chlorambucil arm was 8.8 months. There was no difference in overall survival between the groups. The median OS in the CR and no CR groups was not reached and 75.9 months. (Knauf, W. U., et al. (2012). Br J Haematol 159(1): 67-77.)

Chlorambucil 10 mg/m2 PO daily in single or divided doses for 7 days repeated every 28 days until maximum response, or if partial response for 9-12 months was used in the UK CLL4 study in which the overall response rate was 72%.

Chlorambucil 0.1 mg/kg daily may also be given on a continuous basis as used in a French Cooperative Group study. (The French Cooperative Group on Chronic Lymphocytic Leukemia. (1990). Blood 75(7): 1422-1425.).

A short course of oral steroids has been recommended by some for patients with stage C disease before chlorambucil (grade C, level IV evidence).

For further information, see the Data Sheet on Medsafe.

For avid readers wanting a comprehensive review of the use of chlorambucil in CLL see Goede, V., et al. (2014). "Past, present and future role of chlorambucil in the treatment of chronic lymphocytic leukemia." Leuk Lymphoma: 1-8.

Fludarabine and Cyclophosphamide

Fludarabine and cyclophosphamide have been shown in three randomised controlled trials to result in more complete (24-38%) and overall responses (70-95%) than fludarabine alone (6-15% and 50-83% respectively). In younger patients quality of life was not worse on FC v F. Overall survival was not different between the two groups. Older patients are likely to tolerate the combined regimen less well with a higher rate of infectious complications.

Either IV

Note: Cyclophosphamide should be infused immediately before fludarabine for optimal effect.

Or oral

Note: If patients wish to take the tablets in divided doses, it is recommended to take the cyclophosphamide tablets at breakfast time and the fludarabine tablets at lunchtime. Antiemetic therapy will be required. Start with metoclopramide PO 10-20 mg TDS or cyclizine 25-50 mg PO BD or TDS.

Consider reducing dose fludarabine in elderly.

Do not give fludarabine if:

See below for dosage modifications, adverse effects and supportive needed.

For further information, see the Data Sheets on Medsafe.

Note: Fludarabine (and Cladribine and Pentostatin) requires:

Irradiation of all blood products for at least a year (see Irradiated Blood form).

PCP prophylaxis (co-trimoxazole 480 mg daily) from the start of treatment and continued for six months after therapy ends.

For further information, see the Data Sheets on Medsafe.

Bendamustine and Rituximab

Bendamustine was compared to chlorambucil in a randomised trial. As a single agent, it produced improved responses but greater toxicity and no OS benefit. The overall response and median progression free survival was 67% and 22 months for bendamustine versus 30% and 8 months for chlorambucil.

More recently bendamustine has been combined with rituximab (BR) as a first-line therapy for patients with CLL. In head-to-head comparison with FCR, the median progress free survival was 41.7 months for BR and 55.2 months with FCR. The number of patients achieving MRD negativity was also higher for FCR than BR. However, FCR was associated with more severe neutropenia and infective complications (84% vs 59% and 39% vs 25% respectively), especially in patients >65 years of age. Therefore, FCR remains the standard of care in young fit CLL patients, but elderly fit CLL patients may benefit from this as an alternative regime.

For more information see Eichhorst, B. et al. “First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17:928-942

PHARMAC criteria for Special Authority are:

Bendamustine hydrochloride

Obinutuzumab and Chlorambucil

Obinutuzumab is a humanised anti-CD20 monoclonal antibody that was initially investigated in patients with relapsed/refractory disease where overall response rates of between 30–60% were observed. Based on these results, Obinutuzumab in combination with chlorambucil (O-CLB) was compared to rituximab and chlorambucil (R-CLB), and chlorambucil (CLB) alone in previously untreated patients. Treatment with O-CLB resulted in increased response and prolonged progression-free survival (PFS) compared to R-CLB and CLB (PFS 26.7 months vs 11.1 months vs 16.3 months respectively). Also improved OS compared to CLB alone.

The most common side effect with O-CLB are infusion-related reactions and neutropenia.

For more information see:

Obinutuzumab

Rituximab

PHARMAC criteria for Special Authority are:

About this Canterbury DHB document (5512):

Document Owner:

Andrew Butler (see Who's Who)

Issue Date:

September 2018

Next Review:

September 2021

Keywords:

Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 5512